Other
Jul 2023The CDC ended its Biobot contract in 2023 and replaced it with Verily/WastewaterSCAN, reducing one major federal customer relationship.
SourcePopulation health analytics powered by wastewater.
Company research
Public company, workplace, funding, and market signals
Overview
Biobot Analytics is a Cambridge-based, MIT-born wastewater intelligence company that turns sewage samples into privacy-first, population-level public health and biosecurity insights for governments, healthcare systems, and life-sciences customers.
Primary product
Wastewater intelligence platform (Biobot Advance and related dashboards/API services)
Founded
2017
Headquarters
Cambridge, Massachusetts, United States
Team size
20-30 employees
Work style
Flexible
Industry
Data Infrastructure and Analytics
Sub-industry
Wastewater epidemiology / public health intelligence
Offices
750 Main St, Cambridge, MA 02139
Business model
B2B SaaS
Data-as-a-Service
Managed lab and analytics services
Public-sector and enterprise contracts
Funding
Stage
Venture-backed / growth
Total raised
$91.5M
Latest round
Venture Round · Jun 2025
People & investors
Leadership
CEO & Cofounder
President & Cofounder
Chief Revenue Officer
Chief Product Officer
Vice President Marketing
Investors
Work & culture
Mission-driven, science-heavy, and privacy-first; combines biology, urban/public-health research, data science, and engineering; emphasizes community trust, real-time response, and interdisciplinary problem solving.
Work style
Flexible
Compensation
No official public salary band was found. Public career aggregators and job listings indicate equity, strong benefits, and role-specific pay signals around the mid-$90k range for associate data science roles and around the mid-$140k range for staff engineer roles, plus a 3% 401(k) contribution and other perks.
Benefits
Free medical, dental, and vision insurance for employees and their families
$0 deductible medical plan
Unlimited PTO with a 3-week minimum
12 weeks parental leave at 100% pay
3% 401(k) contribution
$500 home office stipend for remote employees
Free parking and commuter benefits
Free meals for lab employees
Snacks and drinks
Customized development tracks
Job training and conferences
Product & market
Pricing
Quote-based, custom contract pricing / annual service agreements; public reporting suggests municipal engagements can start around $15k per year.
Differentiators
- —Privacy-first community-level analytics; no individual is identifiable
- —First company to commercialize wastewater epidemiology in the U.S.
- —Broad multi-pathogen and multi-substance coverage
- —Metagenomic sequencing that can detect thousands of viruses and microbes
- —Early-warning signals weeks or months ahead of traditional clinical reporting
- —Granular geography from ZIP/county to national dashboards
- —Flexible delivery via dashboards, CSV, and API
Technology
proprietary data and AI
Python
PostgreSQL
AWS
AWS Lambda
Terraform
Auth0
React
Storybook
Snowflake
Docker
Node.js
TypeScript
GitLab CI
Turborepo
esbuild
Ant Design
Visx/D3
qPCR
metagenomic sequencing
Customers
Federal agencies (CDC, HHS, ONDCP, NIH/NIDA, and other public-health or national-security buyers)
State and local public health departments
Municipalities and county governments
Wastewater treatment plants
Pharmaceutical companies
Life sciences companies
Healthcare systems
Vaccine manufacturers
Universities and campuses
Public-health researchers and program evaluators
Competitors
Verily / WastewaterSCAN
State-run in-house wastewater surveillance programs
Other wastewater epidemiology vendors
Tamarind Bio
Scale & contact
Estimated revenue
$20M-$30M
Estimated monthly visits
5.4K
Traffic estimate as of Jul 2026
Signals & risks
Latest news
The Boston Globe · Jul 2026
The Commonwealth of Massachusetts is ending its contract with Biobot on July 31, 2026; the article also notes the CDC ended its contract in 2023 and that Biobot still works with dozens of communities and agencies.
PR Newswire / Biobot Analytics · Jun 2026
Biobot published Nature Water findings showing that near-real-time wastewater intelligence can predict substance-use trends at national scale and led fatal-overdose reporting by 15 months.
PR Newswire / Biobot Analytics · Jan 2026
Biobot won an ONDCP contract to provide nationwide insight on more than 20 chemical targets, extending its federal substance-use monitoring work.
PR Newswire / Biobot Analytics · Jun 2025
Biobot announced a new funding round led by Valor Equity Partners, with Atreides Management joining and Hyperplane participating.
Biobot Analytics · Apr 2024
Biobot and Mathematica reported that wastewater data can detect emerging opioid threats, predict overdoses, and help tailor treatment and program decisions.
Jobs and careers at Biobot Analytics
0 jobs at Biobot Analytics
No open positions
Check back later for new openings